Lupin gets tentative approval from USFDA for Azilsartan Medoxomil Tablets

24 Dec 2021 Evaluate

Lupin has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Azilsartan Medoxomil Tablets, 40 mg, and 80 mg to market a generic equivalent of Edarbi Tablets, 40 mg, and 80 mg, of Arbor Pharmaceuticals, LW. This product will be manufactured at Lupin's Nagpur facility in India.

Azilsartan Medoxomil Tablets (RLD: Edarbi Tablets) had estimated annual sales of $103.4 million in the U.S.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.

Lupin Share Price

1544.80 -48.85 (-3.07%)
19-Apr-2024 13:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1510.95
Dr. Reddys Lab 5894.20
Cipla 1343.90
Zydus Lifesciences 915.15
Lupin 1544.80
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.